ARS Investment Partners’s Novavax NVAX Stock Holding History

ARS Investment Partners’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-500	Closed	-$13K	–	162
2016 Q4	$13K	Buy	+500	New	+$14.6K	﹤0.01%	157

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ARS Investment Partners's NVAX Position: Q1 2017 in Review

ARS Investment Partners sold out of Novavax (NVAX) in Q1 2017, closing a stake of 500 shares — an estimated $13K sold.

ARS Investment Partners first reported a position in NVAX in Q4 2016 and held it in 1 quarter. The position peaked at $13K in Q4 2016. 129 funds tracked by Wall St. Rank hold NVAX as of Q1 2017.

ARS Investment Partners reported no remaining Novavax position as of Q1 2017 after selling out during the quarter.
ARS Investment Partners sold 500 Novavax shares in Q1 2017, an estimated $13K.
ARS Investment Partners first reported a position in Novavax in Q4 2016 and held it in 1 quarter.
ARS Investment Partners's Novavax position peaked at $13K in Q4 2016.
129 funds tracked by Wall St. Rank held Novavax as of Q1 2017.

Based on ARS Investment Partners's 13F filing for Q1 2017, filed 10 May 2017.